IP Library Granted Patent US 11,103,870
Granted Patent B2
US 11,103,870 · App. 16/259,538 · Granted Aug 31, 2021

Methods, systems and devices for selection and generation of genome edited clones

Inventors: Gregory G. Lavieu (Vitry sur Seine, FR); Annamaria Mocciaro (San Francisco, CA); Xiao Guan Radstrom (San Rafael, CA); Jason M. McEwen (El Cerrito, CA); Magali Soumillon (Berkeley, CA); J. Tanner Nevill (El Cerrito, CA); Volker L. S. Kurz (Oakland, CA); Patricia A. Dyck (San Francisco, CA); Ravi K. Ramenani (Fremont, CA)
Assignee: Berkeley Lights, Inc.
B01L3/502761B01L3/502792C12M23/16C12N15/1003C12N15/1024C12N15/1086G01N15/10B01L2200/0647B01L2200/0668B01L2300/0816B01L2300/0864B01L2400/0424B01L2400/0427C12N2310/00C12N2510/00G01N2015/0288G01N2015/1081
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,103,870
App. No.
16/259,538
Granted
Aug 31, 2021
Kind
B2
Abstract

Methods are described herein for isolating clonal populations of cells having a defined genetic modification. The methods are performed, at least in part, in a microfluidic device comprising one or more sequestration pens. The methods include the steps of: maintaining individual cells (or precursors thereof) that have undergone a genomic editing process in corresponding sequestration pens of a microfluidic device; expanding the individual cells into respective clonal populations of cells; and detecting, in one or more cells of each clonal population, the presence of a first nucleic acid sequence that is indicative of the presence of an on-target genome edit in the clonal population of cells. Also described are methods of performing genome editing within a microfluidic device, and compositions comprising one or more clonal populations of cells generated according to the methods disclosed herein.

Claims (37)

1. A method of generating a clonal population of genetically modified cells in a microfluidic device comprising a sequestration pen, the method comprising:

maintaining a first cell in the sequestration pen of the microfluidic device, wherein the first cell has undergone a genome editing process;

expanding the first cell into a clonal population of cells in the sequestration pen;

detecting, in one or more cells of a first subset of the clonal population, the presence of a first nucleic acid sequence, wherein the first nucleic acid sequence indicates the presence of an on-target genome edit in the clonal population of cells; and

preserving a second subset of the clonal population of cells.

2. The method of claim 1 , wherein the first cell is a mammalian cell or an immunological cell.

3. The method of claim 1 , wherein the first cell is a stem or progenitor cell.

4. The method of claim 1 , wherein detecting the first nucleic acid sequence comprises:

selecting one or more cells from the clonal population of cells; and

extracting nucleic acid from the one or more selected cells.

5. The method of claim 4 , further comprising:

moving the one or more selected cells out of the sequestration pen; and

exporting the one or more selected cells from the microfluidic device, wherein the nucleic acid is extracted outside of the microfluidic device.

6. The method of claim 4 , further comprising:

moving the one or more selected cells out of the sequestration pen to a separate region within the microfluidic device, wherein the nucleic acid is extracted in the separate region.

7. The method of claim 1 , further comprising:

detecting, in one of more cells of the clonal population, the presence of a second nucleic acid sequence, wherein the combination of the first nucleic acid sequence and the second nucleic acid sequence indicates the presence of the on-target genome edit in the clonal population of cells.

8. The method of claim 1 , wherein the microfluidic device comprises a substrate that has a dielectrophoresis (DEP) configuration.

9. The method of claim 1 , wherein expanding the first cell into a clonal population of cells further comprises monitoring one or more characteristics of the cells of the clonal population for a period of time.

10. The method of claim 9 , wherein the monitoring comprises assessing the production of a protein of interest, the presence of one or more cell surface markers, and/or reaction with a specific antibody.

11. A method of performing targeted genome editing within a microfluidic device, the method comprising:

selecting a first cell for genome editing;

positioning the first cell within an editing region of the microfluidic device; and

while the first cell is located within the editing region:

contacting the first cell with a genome editing biomolecule, the genome editing biomolecule configured to edit a genome of the first cell at a target site in the genome; and

allowing the genome editing biomolecule to edit the genome of the first cell at the target site.

12. The method of claim 11 , wherein the genome editing biomolecule comprises an endonuclease.

13. The method of claim 11 , wherein the genome editing biomolecule comprises a nucleic acid that encodes an endonuclease.

14. The method of claim 11 , wherein the step of contacting the first cell comprises permeabilizing the first cell.

15. The method of claim 11 , wherein the genome editing biomolecule is associated with a nanoparticle delivery vehicle or microstructure, and wherein contacting the first cell with a genome editing biomolecule comprises contacting the first cell with the nanoparticle delivery vehicle or microstructure.

16. The method of claim 11 , wherein the first cell is a mammalian cell, an immunological cell, a stem cell, or a progenitor cell.

17. The method of claim 11 , wherein the edit to the target site of the genome of the first cell comprises a deletion.

18. The method of claim 11 , wherein the edit to the target site of the genome of the first cell comprises an insertion of an exogenous nucleic acid sequence.

19. The method of claim 1 , further comprising:

exporting one or more cells of a clonal population of genetically modified cells from the microfluidic device into a well plate, and

culturing the one or more exported cells in the well plate.

20. A composition comprising a clonal population of genetically modified cells, wherein the clonal population was generated by the methods of claim 1 .

Assignments (4)
MERGER Recorded Apr 9, 2026
From: BRUKER CELLULAR ANALYSIS, INC.
To: BRUKER SPATIAL BIOLOGY, INC.
Reel/Frame 075375/0517 →
MERGER AND CHANGE OF NAME Recorded Nov 30, 2023
From: PHENOMEX INC.; BIRD MERGERSUB CORPORATION
To: BRUKER CELLULAR ANALYSIS, INC.
Reel/Frame 065726/0624 →
CHANGE OF NAME Recorded Sep 20, 2023
From: BERKELEY LIGHTS, INC.
To: PHENOMEX INC.
Reel/Frame 064961/0794 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2019
From: LAVIEU, GREGORY G.; MOCCIARO, ANNAMARIA; GUAN RADSTROM, XIAO; MCEWEN, JASON M.; SOUMILLON, MAGALI; NEVILL, J. TANNER; KURZ, VOLKER L. S.; DYCK, PATRICIA A.; RAMENANI, RAVI K.
To: BERKELEY LIGHTS, INC.
Reel/Frame 050383/0677 →